Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Southwest Oncology Group
ClinicalTrials.gov Identifier:
NCT00337129
First received: June 13, 2006
Last updated: July 20, 2012
Last verified: July 2012

June 13, 2006
July 20, 2012
May 2006
August 2008   (final data collection date for primary outcome measure)
Response Probability (Confirmed Complete and Partial Responses) [ Time Frame: Every 6 weeks until progression of disease up to a maximum of 3 years after registration ] [ Designated as safety issue: No ]
Response was defined per RECIST. Complete response (CR) was defined as complete disappearance of all baseline measurable and non-measurable disease with no new lesions. Partial response (PR) was defined as at least 30% decrease under baseline of the sum of longest diameters of all target measurable lesions with no unequivocal progression of non-measurable disease and no new lesions. A CR or PR must be confirmed by a second determination at least 4 weeks apart. All disease must have been assessed using the same technique as baseline.
Not Provided
Complete list of historical versions of study NCT00337129 on ClinicalTrials.gov Archive Site
  • Progression-Free Survival [ Time Frame: Every 6 weeks until progression of disease up to a maximum of 3 years after registration. ] [ Designated as safety issue: No ]
    Progression-free survival was defined as the time from date of registration to the date of first documentation of progression or symptomatic deterioration, or death due to any cause. Patients last known to be alive and progression-free were censored at date of last contact.
  • Overall Survival [ Time Frame: Every 3 months for first year, then every six months thereafter up to a maximum of 3 years from registration. ] [ Designated as safety issue: No ]
    Overall survival was defined as the time from the date of registration to the date of death due to any cause. Patients last known to be alive are censored at date of last contact.
  • Toxicity [ Time Frame: Every 3 weeks while on protocol therapy ] [ Designated as safety issue: Yes ]
    The NCI Common Toxicity Criteria for Adverse Events (CTCAE) version 3.0 was utilized.
Not Provided
Not Provided
Not Provided
 
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

RATIONALE: Drugs used in chemotherapy, such as E7389, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This phase II trial is studying how well E7389 works in treating patients with metastatic or recurrent head and neck cancer.

OBJECTIVES:

  • Evaluate the response probability (confirmed, complete, and partial responses) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck treated with E7389.
  • Estimate progression-free and overall survival probability in these patients.
  • Evaluate the qualitative and quantitative toxicities of this treatment regimen.

OUTLINE: This is a multicenter study.

Patients receive E7389 IV on days 1 and 8. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression.

After completion of study treatment, patients are followed periodically for up to 3 years.

PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.

Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Head and Neck Cancer
Drug: eribulin mesylate
1.4 mg/m2 by IV bolus on Days 1 and 8 of an every 21-day cycle.
Other Name: E7389
Experimental: eribulin mesylate
eribulin mesylate
Intervention: Drug: eribulin mesylate
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
42
January 2010
August 2008   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed squamous cell carcinoma of the head and neck (SCCHN)

    • Disease is either metastatic at diagnosis or has persisted, metastasized, or recurred after definitive surgery and/or radiotherapy
    • Not amenable to surgical resection for salvage therapy
    • No newly diagnosed nonmetastatic disease
    • No salivary or nasopharyngeal primary disease
    • Patients who have failed primary surgery alone, and who have disease that is salvageable by radiation or chemoradiation, are not eligible
  • Measurable disease

    • Measurable disease within a previous radiotherapy port must demonstrate clearly progressive disease
  • No active or prior CNS metastasis

PATIENT CHARACTERISTICS:

  • Zubrod performance status 0-1
  • Absolute granulocyte count ≥ 1,500/mm³
  • Platelet count ≥ 100,000/mm³
  • Bilirubin ≤ 2 times upper limit of normal (ULN)
  • SGOT and SGPT ≤ 2 times ULN
  • Creatinine ≤ 2 times ULN
  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • No known HIV positivity
  • No prior malignancies except for the following:

    • Adequately treated basal cell or squamous cell skin cancer
    • In situ cervical cancer
    • Adequately treated stage I or II cancer currently in complete remission
    • Any other cancer for which the patient has been disease free for ≥ 5 years

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • No prior chemotherapy for recurrent or newly diagnosed metastatic disease
  • At least 6 months since prior induction or adjuvant chemotherapy for patients who relapsed after receiving this therapy

    • No more than 1 prior induction or adjuvant regimen (may have included a taxane)
  • More than 2 weeks since prior biologic therapy (i.e., epidermal growth factor inhibitors and vascular endothelial growth factor inhibitors)
  • More than 28 days since prior radiotherapy and recovered
  • More than 28 days since prior surgery and recovered
  • No other concurrent therapy (i.e., radiotherapy, chemotherapy, immunotherapy, biologic therapy, or gene therapy) for SCCHN
  • No concurrent combination antiretroviral therapy for HIV-positive patients
  • No concurrent prophylactic colony-stimulating factors during course 1
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00337129
CDR0000481530, U10CA032102, S0618
No
Southwest Oncology Group
Southwest Oncology Group
National Cancer Institute (NCI)
Study Chair: Susanne M. Arnold, MD Lucille P. Markey Cancer Center at University of Kentucky
Southwest Oncology Group
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP